Programs Brought to Clinic
1 +
Clinical Batches Manufactured
1 +
Core Service Areas
1

100%

Compliance Track Record

ADC ExpertiseAntibody-Drug Conjugate Expertise Across Development and CMC

Specialized ADC support from preclinical planning through commercial readiness

DES Pharma supports ADC programs across cleavable and non-cleavable linker systems, auristatin and maytansinoid payload classes, and both conventional and site-specific conjugation strategies. We help sponsors move from early product concept to a development path that works for manufacturing, analytical control, and regulatory review, translating antibody, linker, and payload choices into practical plans for conjugation, purification, containment, and release testing.

ADC development requires control of more than antibody quality alone. DAR distribution, conjugation-site heterogeneity, free payload, unconjugated antibody, aggregation, fragmentation, and linker stability can all influence batch consistency and filing readiness. Our teams build CMC plans around the attributes that matter most, using methods and control approaches that connect process decisions to product quality, from HIC-HPLC DAR assessment through impurity clearance and stability-indicating analytics.

🔬

ADC CMC Capabilities

Across IND-enabling, clinical, and commercial phases

Linker-Payload Selection

DAR Control & HIC-HPLC

Site-Specific Conjugation

Free Payload Analysis

Containment Strategy

ICH Q6B Specification Design

ICH Q14 / Q2(R2) Lifecycle

Tech Transfer & Scale-Up

Our work spans preclinical development, IND-enabling work, clinical scale-up, tech transfer, process characterization, and commercial readiness planning. We help sponsors shape ADC programs around biologics specification expectations under ICH Q6B and current analytical lifecycle thinking under ICH Q14 and Q2(R2), while keeping the strategy practical, phase-appropriate, and ready for both internal decision-making and health authority review.

ADC CMC StrategyBuilt for the Complexity
of ADC Development

Every ADC program presents a unique intersection of antibody biology, synthetic chemistry, and biopharmaceutical manufacturing. Our teams bring deep experience across the critical control points that determine whether an ADC program advances on schedule, from early molecule design to a GMP-ready process.

Conjugation Process Development

Optimization of conjugation chemistry, reaction conditions, and scale-up parameters for both lysine and cysteine conjugation, as well as engineered site-specific approaches including unnatural amino acid and enzymatic platforms.

DAR Control & Analytical Strategy

Design of DAR distribution targets and control strategies using HIC-HPLC, RPLC-MS, and hydrophobic interaction methods. Alignment of analytical specifications with CMC filing requirements under ICH Q6B and evolving ADC characterization expectations.

Impurity & Free Payload Control

Development of methods for free drug, unconjugated antibody, linker-related impurities, and high-DAR species. Risk-based control strategies aligned with ICH Q3A/Q3B thresholds and potent compound safety considerations.

Containment & GMP Scale-Up

Planning for OEB-appropriate manufacturing environments, contained CDMO evaluation, potent compound handling SOPs, and engineering controls for clinical and commercial ADC manufacturing campaigns.

Regulatory CMC Strategy

Phase-appropriate CMC documentation, IND and BLA section development, Health Authority briefing books, and comparability strategies. Deep familiarity with FDA and EMA expectations for novel ADC modalities and combination product classifications.

Why DES Pharma Driving Results & Impact Real Results at Every Stage

End-to-End Development Support

Expertise across the entire drug product lifecycle, from preclinical IND planning through PPQ and commercial BLA filing.

Efficient, Results-Oriented Approach

Focused on essential experiments and decision-enabling data to accelerate program timelines and reduce development spend.

Robust Quality & Compliance

Ensuring product safety, batch integrity, and regulatory adherence at every stage of your program.

Ensuring product safety, batch integrity, and regulatory adherence at every stage of your program.

Dedicated expertise in potent compound GMP, DAR analytics, linker stability, and site-specific conjugation, beyond general biologics consulting.

Built on Science Built on Science, Focused on Safety

Reliable product quality begins with a strategic, system-driven development process. Our team at DES Pharma applies a disciplined program design that minimizes risk, streamlines operations, and protects patient safety.

For ADC programs, this means integrating potent compound controls, analytical lifecycle management, and risk-based CMC strategies into a single, cohesive development plan, aligned with current regulatory expectations from first-in-human through product approval.

InsightsNews & Blog Articles: Explore Recent Insights

Get Started Advance Your ADC Program
with Confidence

Start building reliable, high-quality ADC development programs today.
Connect with our team to discuss your CMC strategy, analytical needs,
or supply chain requirements.